Genmab A (GMAB) Net Income towards Common Stockholders Growth (1y) (2019 - 2026)
Powered by 
Analysis
Genmab A (GMAB) Net Income towards Common Stockholders Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 65.85% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -635.24% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 6.48% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | -6.81% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 5.21% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 92.37% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 327.74% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -84.64% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | -64.26% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -64.26% |
| Mar 31, 2026 | 7.29% |
| Sep 30, 2025 | 87.66% |
| Jun 30, 2025 | 303.27% |
| Mar 31, 2025 | 69.08% |
| Sep 30, 2024 | 6.98% |
| Jun 30, 2024 | 23.59% |
| Mar 31, 2024 | 20.93% |
| Dec 31, 2023 | -3,568.93% |
| Sep 30, 2023 | 13.11% |
| Jun 30, 2023 | -36.50% |
| Dec 31, 2022 | 103.22% |
| Sep 30, 2022 | 2.83% |
| Jun 30, 2022 | 50.06% |
| Dec 31, 2021 | -235.75% |
| Sep 30, 2021 | -86.67% |
| Jun 30, 2021 | -62.16% |
| Mar 31, 2021 | 302.26% |
| Dec 31, 2020 | -86.64% |
| Sep 30, 2020 | 2,542.29% |